Merck & Co. (NYSE:MRK) has emerged as a standout defensive play in the current market environment, with shares up 41% year to date. On the September 8 episode of Mad Money, Jim Cramer identified Merck as his top pick for a fantasy football "defense/special teams" slot, citing the pharmaceutical giant's ability to limit downside while offering significant upside catalysts.

Market Context

The broader healthcare sector has shown resilience amid macroeconomic uncertainty, with defensive names outperforming growth stocks. Merck’s performance reflects this rotation, driven by its status as a stable revenue generator that performs well even in adverse economic conditions or rising interest rate environments. Cramer noted that while traditional defensive stocks offer stability, Merck provides additional "special teams" upside through high-impact biotech developments.

Analysis

Cramer’s thesis rests on Merck’s dual nature: inherently defensive due to its essential drug portfolio, yet capable of explosive growth through partnerships. He specifically pointed to the collaboration with Moderna, noting that promising results from their melanoma vaccine trial provided the kind of upside typically associated with offensive picks. This mirrors the LA Rams defense analogy Cramer used—high-performing but racing against a clock. For Merck, that clock is the looming patent expiration for its blockbuster drug Keytruda in 2028, which forces management to aggressively fund new pipeline assets to offset future revenue cliffs.

Key Numbers

- MRK shares are up 41% year to date.

- Q2 worldwide sales reached $16.6 billion.

- Keytruda franchise (IV and subcutaneous QLEX) generated $8.4 billion in Q2 revenue.

- Winrevair sales surged 75% to $588 million in Q2.

- Management raised full-year 2026 sales guidance to $66.3 billion–$67.3 billion.

- Keytruda loss of exclusivity is projected for late 2028.

What to Watch

Investors should monitor Merck’s pipeline progress, particularly the mRNA cancer vaccine collaboration with Moderna, as these assets are critical to bridging the revenue gap post-Keytruda. Clinical trial updates, regulatory approvals, and any shifts in guidance regarding the 2026 sales range will be key catalysts. The market will also weigh the risks associated with these new partnerships, including manufacturing and commercialization hurdles, against the defensive stability of the core oncology business.